

RESEARCH

Open Access



Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy

Davide Chiumello^{1,2,3*} , Alessandro Tavelli⁴, Lorenzo Serio², Sara De Benedittis⁴, Tommaso Pozzi², Roberta Maj^{5,6}, Mara Velati^{5,6}, Serena Brusatori⁵, Rosanna D'Albo⁵, Carmelo Zinnato⁵, Giulia Marchetti^{2,4}, Luigi Camporota⁷, Silvia Coppola¹ and Antonella D'Arminio Monforte^{2,4}

Abstract

Background To evaluate the differences in the clinical characteristics and severity of lung impairment, assessed by quantitative lung CT scan, between vaccinated and non-vaccinated hospitalized patients with COVID-19; and to identify the variables with best prognostic prediction according to SARS-CoV-2 vaccination status. We recorded clinical, laboratory and quantitative lung CT scan data in 684 consecutive patients [580 (84.8%) vaccinated, and 104 (15.2%) non-vaccinated], admitted between January and December 2021.

Results Vaccinated patients were significantly older 78 [69–84] vs 67 [53–79] years and with more comorbidities. Vaccinated and non-vaccinated patients had similar PaO₂/FiO₂ (300 [252–342] vs 307 [247–357] mmHg; respiratory rate 22 [8–26] vs 19 [18–26] bpm); total lung weight (918 [780–1069] vs 954 [802–1149] g), lung gas volume (2579 [1801–3628] vs 2370 [1675–3289] mL) and non-aerated tissue fraction (10 [7.3–16.0] vs 8.5 [6.0–14.1] %). The overall crude hospital mortality was similar between the vaccinated and non-vaccinated group (23.1% vs 21.2%). However, Cox regression analysis, adjusted for age, ethnicity, age unadjusted Charlson Comorbidity Index and calendar month of admission, showed a 40% reduction in hospital mortality in the vaccinated patients (HR_{adj} = 0.60, 95%CI 0.38–0.95).

Conclusions Hospitalized vaccinated patients with COVID-19, although older and with more comorbidities, presented a similar impairment in gas exchange and lung CT scan compared to non-vaccinated patients, but were at a lower risk of mortality.

*Correspondence:

Davide Chiumello
davide.chiumello@unimi.it

¹ Department of Anesthesia and Intensive Care, ASST Santi Paolo e Carlo, San Paolo University Hospital, Via Di Rudini 9, Milan, Italy

² Department of Health Sciences, University of Milan, Milan, Italy

³ Coordinated Research Center on Respiratory Failure, University of Milan, Milan, Italy

⁴ Infectious Diseases Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo University Hospital, Milan, Italy

⁵ Department of Anesthesiology, Medical University of Göttingen, University Medical Center Göttingen, Göttingen, Germany

⁶ Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁷ Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, UK

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected more than 500 million people and caused more than 6 million deaths worldwide [1]. During the pandemic, control measures, such as isolation, social distancing and the use of face masks, were utilized to limit viral transmission, but were ultimately insufficient to alter the course of the pandemic and the mortality rate [2]. Vaccination aims to increase population immunity, prevent severe disease, and reduce the hospitalization risk [3]. Different types of vaccines have been developed, each with up to 90–95% efficacy for preventing COVID-19 and its related mortality [4–6]. Based on these data, in December 2020 a program of vaccination for adults was launched in Europe and in the United States [7, 8].

In Lombardy (Northern Italy) at the end of 2021, 85% of the population aged 20 years or older, had completed the full primary cycle of COVID-19 vaccination (i.e., the ratio between vaccinated to non-vaccinated = 5.6). By the end of 2022, 87.3% of the Lombardy population aged 20 years or older had completed the primary vaccination course, but the remainder of the target population were still unvaccinated almost 2 years after starting the vaccination campaign in Italy [9].

Adequate protection following vaccination requires a competent immune response and breakthrough infection in vaccinated patients has been reported [10–13]. In vaccinated patients the main risk factors associated with hospital admission were the presence of immunosuppression, older age and cardiac or respiratory failure [11, 14–16].

A smaller proportion of vaccinated patients was admitted to hospital or to intensive care (ICU), received mechanical ventilation or experienced disease progression [15–17]. However, the hospital [15–17] and ICU mortality [18–21] were similar between vaccinated and not vaccinated patients and ranged between 6% and 22%.

Morphological analysis of lung CT scan is considered the modality of choice to evaluate the severity, extent of parenchymal disease and the presence of pulmonary vascular alterations. Furthermore, CT scan can easily detect gastrointestinal, renal and brain injury and predict the risk of clinical deterioration [22–26]. In addition, through quantitative lung CT analysis it is possible to accurately compute lung weight, gas volume, and the amount of aerated and non-aerated lung tissue, which have been previously associated with outcome in patients with non-COVID-19 ARDS [27, 28]. Few studies applied quantitative lung CT analysis in mechanically ventilated COVID-19 patients [29, 30] and it is unclear whether vaccination affects the clinical and radiological severity of hospitalized COVID-19 patients and their survival.

This study aims to evaluate the clinical characteristics and the quantitative lung CT features in vaccinated and not vaccinated hospitalized COVID-19 patients on admission. Moreover, this study aims to establish whether clinical and radiological variables can predict outcome according to vaccination status.

Materials and methods

Study design

This was a prospective observational cohort study including patients aged 18 years or older, with a positive polymerase chain reaction (PCR) test for SARS-CoV-2 admitted to San Paolo Hospital of Milan, Italy (ASST Santi Paolo Carlo) between January, 1st and December, 31st 2021. Patients who died in the Emergency Department within 24 h from presentation or those who were not hospitalized were excluded. The study was approved by the institutional review board of the ASST Santi Paolo e Carlo Hospital (protocol number 2020/ST/049 and 2020/ST/049bis, 11 March 2020).

Clinical and laboratory data collection

We collected demographic, laboratory and clinical data at hospital admission (see supplement); lung CT scan within 24 h from admission; physiological and clinical data during ICU admission, as well as the use of monoclonal antibodies, remdesivir, dexamethasone, biological immunomodulatory agents and low molecular weight heparin, and hospital outcome.

Definition of variables

SARS-CoV-2 vaccination status was categorized as follows: (1) not vaccinated (no dose of SARS-CoV-2 vaccine administered before hospital admission); (2) partial vaccination with only one dose, or two doses but with the second administered less than 14 days prior to admission); (3) fully vaccinated (patients who received the second dose of vaccination at least 14 days before admission or patients who had received three vaccination doses) [4, 5, 31].

Lung CT quantitative analysis

Patients underwent lung CT scan acquisition, spontaneously breathing without any non-invasive or invasive ventilatory support. The lung images were processed and analyzed by a dedicated software capable of performing automatic segmentation (Maluna 3.14, Maluna 2020 [32]). The total lung weight, the total lung gas volume, and the amount of the different compartments (not aerated, poorly aerated, normally aerated and over aerated) were computed using a previously described dedicated software (Maluna 3.14, Maluna 2020) [32, 33].

Statistical analysis

Characteristics of the study participants, assessed at hospital admission, were compared after stratification by SARS-CoV-2 vaccination status and hospital outcome. Qualitative data are reported as frequencies and percentages, whereas continuous data are presented as mean (SD) or median [IQR], as appropriate.

Continuous variables were compared using Mann–Whitney *U* test. Categorical variables were compared by Chi-square test.

The odds ratio (OR) of death was also adjusted for age, to account for differences in age distribution in the two populations that may have different vaccination rates.

Role of SARS-CoV-2 vaccination on quantitative CT-scan-derived lung parameters was analyzed by means of *t* test and linear regression models, unadjusted and adjusted for identified confounders (age, calendar month of admission, chronic lung diseases, ethnicity and sex) (see Additional file 1: Fig. S3A). For the variable including not aerated and poorly aerated fraction of the total lung weight, a quantile regression was adopted.

The probability of ICU admission in fully vaccinated and not vaccinated COVID-19 patients was investigated by a logistic regression model crude and adjusted for age, Charlson Comorbidity Index, PaO₂/FiO₂ at admission and month of admission.

Standard survival analysis with Kaplan–Meier curves and log-rank test were used to estimate the probability of in-hospital death. The time-to-event was calculated from the date of hospital admission to the date of death or last day of hospitalisation. We evaluated the possible association between the different CT-scan lung parameters and time to in-hospital death using unadjusted and adjusted Cox-proportional hazard regression models for each parameter. To investigate this association, we dichotomized the continuous variables of CT-scan using ROC curves and Youden Index (J) method to identify the optimal cutoff for the in-hospital death endpoint. The following variables were considered as confounders (age, age-unadjusted Charlson Comorbidity Index, ethnicity, inflammation, sex and SARS-CoV-2 vaccination status) using the same approach with previously showed DAG (DAG in Additional file 1: Fig. S3C).

The association between vaccination status and the risk of in-hospital death was evaluated by means of Cox regression models, adjusting for factors identified as confounders (age, age-unadjusted Charlson Comorbidity Index, ethnicity, month of admission) (Directed acyclic diagram, DAG in Additional file 1: Fig. S3B).

Results

Clinical characteristics and quantitative lung CT scan data at hospital admission

Among 1016 patients admitted to the hospital in the year 2021, 796 had a lung CT scan on admission, and 684 patients were included in the study (see Additional file 1: Fig. S1); 104 (15.2%) were fully vaccinated and 580 (84.8%) were not vaccinated. Among fully vaccinated patients, 20 (19.2%) completed the full primary vaccination course with ChAdOx1, eight (7.7%) with Ad26.COV2.S, eight (7.7%) with mRNA-1273, and 68 (65.4%), with BNT162b2 vaccine. Eleven patients (10.6% of fully vaccinated, 1.6% of study population) had also a third dose of vaccine: eight with BNT162b2 and three with mRNA-1273.

The baseline characteristics of the population are shown in Table 1.

Patients were admitted to the hospital after a median of 5 [3–6] days from symptoms onset.

Vaccinated patients were significantly older 78 [69–84] vs 67 [53–79] years and with more comorbidities, such as hypertension (52.9% vs 42.2%), ischemic heart disease (21.1% vs 8.3%), COPD (22.1% vs 7.1%) and chronic kidney disease (12.5% vs 6.0%).

Vaccinated and not vaccinated patients had similar PaO₂/FiO₂ (300 [252–342] vs 307 [247–357] mmHg; respiratory rate 22 [8–26] vs 19 [18–26] bpm) (Table 2, Fig. 1); total lung weight (918 [780–1069] vs 954 [802–1149] g), lung gas volume (2579 [1801–3628] vs 2370 [1675–3289] mL) and not aerated tissue fraction (10 [7.3–16.0] vs 8.5 [6.0–14.1] %) (Table 2). In addition, the sum of not aerated and poorly aerated lung tissue fraction was higher in fully vaccinated compared to not vaccinated in the adjusted quantile-regression (36.7% vs 29.3%) (Additional file 1: Table S4A).

Intensive care unit admission

Two fully vaccinated (0.29%) and 26 (4.5%) not vaccinated patients were admitted in the ICU. Fully vaccinated patients had a lower probability of being admitted to ICU compared to not vaccinated after fitting a logistic regression model adjusted for age, Charlson Comorbidity Index, PaO₂/FiO₂ at admission and semester of admission (OR=0.18, 95%CI 0.04–0.85). The comparison in the non-vaccinated group between patients admitted to ICU and those treated outside ICU are reported in Additional file 1: Table S7.

Outcome

One hundred forty-seven patients (21.5%) died in hospital. Among the non-survivors, 12 (8.1%) were admitted to ICU. The clinical data of the patients according to

Table 1 Clinical characteristics at hospital admission of not vaccinated and fully vaccinated patients.

	Total n = 684	Not vaccinated n = 580 (84.8%)	Fully vaccinated n = 104 (15.2%)	p
<i>Demographic characteristics</i>				
Age, years	69 [55–80]	67 [53–79]	78 [69–84]	< 0.001
Male sex, n (%)	398 (58.2)	334 (57.6)	64 (61.5)	0.452
Caucasian, n (%)	600 (87.7)	502 (86.5)	98 (94.2)	0.566
Latin/hispanic, n (%)	24 (3.5)	22 (3.8)	2 (1.9)	
Other, n (%)	60 (8.7)	56 (9.7)	4 (3.8)	
<i>Underlying comorbidities</i>				
Hypertension, n (%)	300 (43.9)	245 (42.2)	55 (52.9)	0.044
Stroke, n (%)	33 (4.8)	26 (4.5)	7 (6.7)	0.325
AMI, n (%)	70 (10.2)	48 (8.3)	22 (21.1)	< 0.001
Diabetes, n (%)	133 (19.4)	104 (17.9)	29 (27.9)	0.018
Cardiovascular diseases n (%)	135 (19.7)	96 (16.5)	39 (37.5)	< 0.001
COPD, n (%)	64 (9.4)	41 (7.1)	23 (22.1)	< 0.001
History of cancer, n (%)	58 (8.5)	38 (6.6)	20 (19.2)	< 0.001
CKD, n (%)	48 (7)	35 (6)	13 (12.5)	0.017
Chronic liver disease, n (%)	15 (2.2)	9 (1.6)	6 (5.8)	0.007
Age-adjusted Charlson score	3 [1–4]	3 [1–4]	4 [3–6]	< 0.001
<i>Laboratory data</i>				
Haemoglobin, g/dL	13.5 [12.0–14.7]	13.7 [12.2–14.9]	12.9 [11.3–14.1]	0.005
CRP, mg/L	52.9 (29.2–84.2)	52.2 [27.1–82.1]	60.6 [35.9–102.8]	0.018
LDH, U/L	293 [235–380]	297 [246–397]	263 [215–338]	0.002
Leukocytes count, 10 ³ /μL	6.21 [4.65–8.72]	6.1 [4.51–8.73]	6.64 [4.65–8.7]	0.382
Platelets, 10 ³ /μL	186 [144–247]	186 [146–239]	183 [135–260]	0.910
D-Dimer, ng/μL	320 [211–616]	314 [214–606]	383 [196–690]	0.562
GPT, U/L	29 [19–49]	30 [20–51]	24 [17–43]	0.086
GOT, U/L	44 [19–49]	44 [34–63]	39 [29–60]	0.086
Creatinine, mg/dL	0.9 [0.7–1.2]	0.8 [0.7–1.1]	1 [0.8–1.5]	< 0.001
Procalcitonin, μg/L	0.17 [0.07–0.63]	0.17 [0.07–0.73]	0.22 [0.18–0.26]	0.636
Ferritin, ng/mL	339 [186–692]	357 [182–708]	314 [305–442]	0.960
<i>Pharmacological treatments</i>				
Remdesivir, n (%)	174 (25.4)	169 (29.1)	5 (4.8)	< 0.001
Heparin profilaxis, n (%)	561 (82)	479 (82.6)	82 (78.8)	0.360
Corticosteroid treatment, n (%)	579 (84.6)	495 (85.3)	84 (80.8)	0.233
Biological immunomodulator, n (%)	49 (7.2)	42 (7.2)	2 (1.9)	0.024
Monoclonal antibodies, n (%)	50 (7.3)	22 (3.8)	28 (26.9)	< 0.001

Continuous variables are expressed as median [IQR] and compared with Mann–Whitney *U* test, while categorical data are expressed as *n* (%) and compared with Chi-square test

COPD chronic obstructive pulmonary disease, *AMI* acute myocardial infarction, *CKD* chronic kidney disease, *CRP* C-reactive protein, *LDH* lactate dehydrogenase, *GOT* glutamic–oxalacetic transaminase, *GPT* glutamate–pyruvate transaminase. History of cancer was defined as a cancer diagnosis in the last 5 years

the hospital outcome is shown in Table 3. Patients who died were significantly older (81 [52–76] vs 64 [74–86] years) and were more likely to have a medical history of hypertension, stroke, myocardial infarction, COPD and cancer. The PaO₂/FiO₂ was significantly higher (309 [185–323] vs 255 [266–347] mmHg) in survivors, while the respiratory rate was not different (Table 4).

Concerning the lung CT scan data, the lung gas volume was significantly higher, while the lung weight and the percentage of not aerated, and poorly aerated were significantly lower in survivors (Table 4).

The Kaplan–Meier curves showed a significantly higher cumulative probability of hospital mortality for a lung tissue weight > 1001 g (log-rank *p* = 0.011), for a lung gas volume < 2089 ml (log-rank *p* = 0.007) and for

Table 2 Respiratory function and lung CT scan quantitative data at hospital admission in not vaccinated and fully vaccinated patients

	Total n = 684	Not vaccinated n = 580 (84.8%)	Fully vaccinated n = 104 (15.2%)	p
<i>Respiratory function</i>				
Respiratory rate, breaths/min	22 [18–26]	22 [8–26]	19 [18–26]	0.254
PaO ₂ /FiO ₂ mmHg	300 [252–342]	300 [252–342]	307 [247–357]	0.454
PaO ₂ , mmHg	69 [20–81]	68 [60–81]	70 [61–82]	0.631
PaCO ₂ , mmHg	33 [30–36]	33 [30–36]	33 [30–37]	0.631
<i>Lung CT scan quantitative data</i>				
Total gas volume, ml	2383 [1697–3312]	2370 [1675–3289]	2579 [1801–3628]	0.145
Total lung weight, g	949 [798–1134]	954 [802–1149]	918 [780–1069]	0.125
Over aerated lung weight, %	2 [0.6–5.4]	1.8 [0.5–5.0]	3.5 [1.5–6.9]	<0.001
Normally aerated lung weight, %	60.3 [51.1–67.5]	60.4 [51.4–67.6]	59.4 [49.3–66.6]	0.432
Poorly aerated lung weight, %	24.8 [18.9–32.5]	25.2 [19.3–32.8]	22.5 [17.9–29.5]	0.043
Not aerated lung weight, %	8.9 [6.2–14.5]	8.5 [6–14.1]	10 [7.3–16.0]	0.031

Continuous variables are expressed as median [IQR] and compared with Mann–Whitney U test.

FiO₂ inspired fraction of O₂, PaO₂ arterial partial pressure of O₂, PaCO₂ arterial partial pressure of CO₂




Fig. 1 Comparisons between fully vaccinated and not vaccinated (unvaccinated) patients in PaO₂/FiO₂ (A), respiratory rate (B), total lung weight (C) and total lung gas volume (D). Continuous variables were compared using Mann–Whitney U test.

Table 3 Clinical characteristics at hospital admission of survivors and non survivors patients

	Survivors n = 537 (78.5%)	Non survivors n = 147 (21.5%)	p
<i>Demographic characteristics</i>			
Age, years	64 [52–76]	81 [74–86]	<0.001
Male gender, n (%)	314 (58.5)	84 (57.1)	0.772
Caucasian, n (%)	459 (85.5)	141 (95.9)	0.012
Latin/hispanic n (%)	24 (4.5)	0 (0.0)	
Other, n (%)	54 (10.0)	6 (4.1)	
<i>Underlying comorbidities</i>			
Hypertension, n (%)	217 (40.4)	83 (56.5)	0.001
Stroke, n (%)	17 (3.2)	16 (10.9)	<0.001
AMI, n (%)	42 (7.8)	28 (19.0)	<0.001
Diabetes, n (%)	100 (18.6)	33 (22.4)	0.299
Cardiovascular diseases, n (%)	88 (16.4)	47 (32.0)	<0.001
COPD, n (%)	39 (7.3)	25 (17.0)	<0.001
History of cancer, n (%)	32 (6.0)	26 (17.7)	<0.001
CKD, n (%)	27 (5.0)	21 (14.3)	<0.001
Chronic liver disease, n (%)	13 (2.4)	2 (1.34)	0.437
Age-adjusted Charlson score	2 (1–4)	5 (4–6)	<0.001
<i>Laboratory data</i>			
Haemoglobin, g/dL	13.7 [12.2–14.8]	12.8 [11.1–14.3]	0.009
CRP, mg/L	50.5 [24.9–81.9]	62.1 [38.0–102.7]	0.001
LDH, U/L	287 [232–372]	307 [256–411]	0.035
Leukocytes count, 10 ³ /μL	6.16 [4.60–8.41]	6.70 [4.28–10.18]	0.143
Platelets, 10 ³ /μL	186 [147–242]	191 [134–252]	0.863
D-Dimer, ng/mL	274 [192–553]	476 [289–854]	<0.001
GPT, U/L	30 [21–53]	23 [17–39]	<0.001
GOT, U/L	42 [32–61]	47 [36–63]	0.246
Creatinine, mg/dL	0.9 [0.7–1.1]	1.1 (0.8–1.5)	<0.001
Procalcitonin, μg/L	0.14 [0.05–0.84]	0.20 (0.11–0.57)	0.273
Ferritin, ng/mL	321 [189–634]	469 [117–991]	0.428
<i>Pharmacological treatments</i>			
Remdesivir, n (%)	148 (27.6)	26 (17.7)	0.015
Heparin profilaxis, n (%)	446 (83.0)	116 (78.9)	0.245
Corticosteroid treatment, n (%)	447 (83.2)	130 (88.4)	0.124
Biological immunomodulator, n (%)	38 (7.1)	12 (8.2)	0.654
Monoclonal antibodies, n (%)	50 (7.3)	22 (3.8)	0.180

Continuous variables are expressed as median [IQR] and compared with Mann–Whitney *U* test, while categorical data are expressed as *n* (%) and compared with Chi-square test

COPD chronic obstructive pulmonary disease, AMI acute myocardial infarction, CKD chronic kidney disease, CRP C-reactive protein, LDH lactate dehydrogenase, GOT glutamic–oxalacetic transaminase, GPT glutamate–pyruvate transaminase. History of cancer was defined as a cancer diagnosis in the last 5 years

a not aerated plus poorly aerated fraction $\geq 41.4\%$ (log-rank $p < 0.001$) (Fig. 2).

The Cox Regression Models adjusted for age, ethnicity, age-unadjusted Charlson Comorbidity Index, sex, SARS-CoV-2 vaccination status and CRP level, showed a 85% higher risk of hospital mortality for subjects with total lung weight > 1001 g ($HR_{adj} = 1.85$, 95%CI 1.28–2.68), a 45% higher risk for patients with a lung gas

volume < 2089 ml ($HR_{adj} = 1.45$, 95%CI 1.01–2.08) and a 2.11-fold increase for those with a not aerated plus poorly aerated fraction $\geq 41.4\%$ (95% CI 1.51–2.96) (Additional file 1: Table S5A–C).

The overall crude hospital mortality was not different between fully vaccinated and not vaccinated patients (23% vs 21.2%, $p = 0.669$). The Kaplan Meier curve of hospital survival did not show any significant difference

Table 4 Respiratory function and lung CT scan quantitative data at hospital admission in survivors and non survivors patients

	Survivors n = 537 (78.5%)	Non survivors n = 147 (21.5%)	p
<i>Respiratory function</i>			
Respiratory rate, breaths/min	20 [17–25]	23 [20–56]	0.115
PaO ₂ /FiO ₂	309.5 [266.7–347.6]	255.7 [185.7–323.8]	<0.001
PaO ₂ , mmHg	69.0 [61.0–80.4]	68.7 [56.9–84.0]	0.355
PaCO ₂ , mmHg	33.5 [30.5–36.7]	32.0 [29.5–36.0]	0.015
<i>Lung CT scan quantitative data</i>			
Total gas volume, ml	2476 [1733–3425]	2023 [1435–2623]	<0.001
Total lung weight, g	938 [792–1121]	991 [810–1202]	0.064
Over aerated lung weight, %	2.2 [0.6–5.8]	1.5 [0.6–4.2]	<0.020
Normally aerated lung weight, %	61.9 [53.8–68.3]	51.8 [41.4–62.0]	<0.001
Poorly aerated lung weight, %	23.7 [18.1–30.3]	30.5 [23–39.3]	<0.001
Not aerated lung weight, %	8.4 [6–12.8]	11.5 [7.1–18.5]	<0.001

Continuous variables are expressed as median [IQR] and compared with Mann–Whitney *U* test

FiO₂ inspired fraction of O₂, PaO₂ arterial partial pressure of O₂, PaCO₂ arterial partial pressure of CO₂

between the two groups (Additional file 1: Fig. S5A, log rank $p=0.688$). Similarly, the median hospital length of stay was not different (12 [7–20] vs 14 [8–22] days, $p=0.57$).

However, Cox regression analysis, adjusted for age, ethnicity, age-unadjusted Charlson Comorbidity Index and calendar month of admission, using the not vaccinated group as comparator, fully vaccinated patients showed a statistically significant twofold risk reduction of hospital death (HR_{adj} = 1.96, 95%CI 1.66–2.32) (Additional file 1: Table S5D). Results were confirmed after restricting for the second semester of 2021, where the main circulating variant of concern was Delta (HR_{adj} = 2.25, 95%CI 1.10–4.60) (Additional file 1: Table S5E).

Discussion

The main findings of this observational study in hospitalized COVID-19 patients were: (1) fully vaccinated patients had a similar degree of lung involvement but were older and with more comorbidities compared to patients who were not vaccinated; (2) the crude hospital and ICU mortality rates were not different among fully vaccinated and not vaccinated patients; and (3) the adjusted hospital mortality rate was significantly lower in fully vaccinated patients.

In Lombardy, up to 89% of the population had been fully vaccinated mainly with mRNA vaccines Comirnaty (BioNTech-Pfizer) and Spikevax (Moderna). It has been reported that the US SARS-CoV-2 vaccination programme was able to prevent up to 56% of all expected hospitalization from December 2020 to September 2021 [3]. Vaccinated patients requiring hospital admission

were mainly older patients with comorbidities [11, 12, 14–16].

Although the vaccine efficacy decreases with time, it can remain high (>70%) at 6 months [12]. In addition, with the emergence of new SARS-CoV-2 variants a reduction in the risk of hospital admission with the variant Omicron compared with the Delta infection was observed [34]. This risk reduction was similar among the fully vaccinated and not vaccinated patients [34]. In this study we observed that there was a significantly lower risk for hospital admission in fully vaccinated patients.

At hospital admission, fully vaccinated patients were older with a higher prevalence of comorbidities compared to not vaccinated patients.

However, the gas exchange (i.e., the PaO₂/FiO₂, PaCO₂) and the respiratory rate were not different between the two populations, suggesting a similar degree of impairment in lung function. In contrast, Tenforde et al., recruiting only patients admitted in hospital with hypoxemia, found a lower number of cases in fully vaccinated compared to not vaccinated (13.5% vs 28.2%) [10]. Regardless of the vaccination status, the current population had on average a similar respiratory rate but a better oxygenation compared to the hospitalized patients during the first wave [35–37].

Concerning the morphological lung abnormalities, the most common non-specific findings in hospitalized patients with COVID-19 included multifocal consolidation and ground glass opacities mainly located in the subpleural space, with a peak of severity within the first week of hospital admission [22, 38]. Applying a morphological analysis, Balacchi et al. did not show any difference




Fig. 2 Kaplan–Meier curves according to lung tissue weight (under and above or equal to 1001 g, **A**), to lung gas volume (under and above or equal to 2089 ml, **B**) and to not aerated plus poorly aerated fraction (under and above or equal 41.4%, **C**). The probability of in-hospital death was assessed by log-rank test.

regarding the CT pattern abnormality between the first and second wave of the pandemic [39, 40].

To quantify the lung involvement, a CT severity score was proposed which is based on the sum of all the individual lobar score (each lobar score can range from 0 to 5) [41]. According to this score, the lung involvement is categorized as mild, moderate or severe for a score lower

than 7, between 8 and 17 and higher than 18, respectively. Fatima et al., reported a similar proportion of patients with moderate and severe lung severity score in fully vaccinated and not vaccinated patients (32% vs 28% and 42% vs 46%, respectively) [41]. Alternatively, the quantitative analysis previously applied in patients with acute respiratory failure, although time consuming and requiring a dedicated software, is considered the best standard lung imaging technique [27, 42]. This analysis is able to accurately assess the lung gas volume, lung weight and the different lung regions (from not aerated to hyperinflated), which are associated with the severity of lung impairment, degree of hypoxemia and hospital outcome [27–29]. To date, there is no study which has evaluated the possible difference in the lung characteristics and impairments in spontaneous breathing fully vaccinated and not vaccinated patients. Our study shows that the lung gas volume, lung weight and total amount of not aerated and poorly aerated lung regions were similar between the two groups. Moreover, in fully vaccinated patients the amount of the sum of not aerated and poorly aerated lung regions were on average less than 34%, suggesting a minimal presence of lung disease. Previous studies in not vaccinated mechanically ventilated COVID-19 ARDS patients reported both a higher lung weight and a greater extension of the non-aerated and poorly aerated lung regions, compared to our study population [30, 43, 44].

Hospital and intensive care outcome

Since the beginning of the pandemic, the mortality rate has decreased to less than 30% in hospitalized patients [10, 15, 17, 45]. We observed that non-survivors were significantly older, presented with a higher number of comorbidities and had a lower lung gas volume with a higher proportion of non-aerated and poorly aerated lung regions, suggesting a higher impairment and extension of lung abnormalities.

Concerning the hospital mortality rate, we did not find any difference among the two groups (fully vaccinated 21.2% vs not vaccinated 23.1%). Similarly, observational studies analyzing hospitalized patients with COVID-19 during the period between February and November 2021 reported that the mortality rate was not different for vaccinated and not vaccinated [45].

These data may suggest that hospitalized vaccinated patients with COVID-19 showed a similar risk of death compared to not vaccinated. However, vaccinated patients are generally older with a higher prevalence of underlying risk factors than not vaccinated. Thus, in our study, when the risk of death was adjusted for age, the adjusted mortality rate was significantly lower in fully vaccinated patients. Similarly, Tenforde et al. found that the progression to death after COVID-19 hospitalization

was associated with a lower likelihood of vaccination and the hospital discharge within 28 days from admission was experienced by a higher number of vaccinated patients when adjusted for age [10].

Considering the whole study population, only a minority was admitted to the intensive care, with less than 5% of not vaccinated patients. Similarly, the ICU outcome was not different between fully vaccinated and not vaccinated patients. The observed mortality rate of the present study was similar to those reported from previous studies [18, 19, 46].

Possible limitations of the present study can be found. This was an observational monocentric study performed in Italy. The determination of the variant of SARS-CoV-2 and the viral load were not performed. Information about other co-infections in the first 48–72 h from hospital admission, which could influence in-hospital mortality, were not collected.

In conclusion, the present data showed that hospitalized vaccinated patients although older and with higher comorbidities, presented a similar impairment both of gas exchange and lung CT scan compared to not vaccinated but a lower risk of mortality.

Abbreviations

SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
COVID-19	Coronavirus disease 19
ICU	Intensive care unit
CT	Computed tomography
PCR	Polymerase chain reaction
OR	Odds ratio
ROC	Receiver operating characteristics
DAG	Directed acyclic graph
PaO ₂	Arterial oxygen partial pressure
FiO ₂	Inspired oxygen fraction.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13613-023-01103-2>.

Additional file 1: Figure S1. Study Flowchart. **Figure S2.** Prevalence of vaccination by month of admission 2021. **Table S1.** Outcomes of not vaccinated and fully vaccinated patients. **Table S2.** Maximum Respiratory Support during hospitalization of not vaccinated and fully vaccinated patients. **Table S3.** Maximum Respiratory Support during hospitalization of survivors and not survivors. **Table S4.** Lung CT scan quantitative data after linear regression model adjusted for age, month of admission, presence of chronic lung diseases, ethnicity and sex (A) overall for January–December 2021 and (B) Only for patients admitted in July–December 2021. **Figure S3.** Underlying assumptions regarding the causal links between variables for estimating the: (A) effect of COVID-19 vaccination on lung CT-scan parameters; (B) effect of COVID-19 vaccination on in-hospital death; (C) effect of lung CT-scan parameters on in-hospital death. **Figure S4.** Histograms of fraction of total lung weight. **Table S5.** Unadjusted and adjusted HR from fitting a standard Cox regression model Of in hospital death by (A) total lung tissue mass strata, (B) Lung gas volume strata, (C) Not aerated plus poorly aerated fraction of total lung weight, (D) Vaccination status (January–December 2021), (E) Vaccination status (only July–December 2021). **Table S6.** Probability of admission in ICU in vaccinated and non-vaccinated COVID-19 patients has been

investigate by means of logistic regression model crude and adjusted for age, Charlson Comorbidity Index, PaO₂/FiO₂ at admission and period of admission. **Table S7.** Clinical Characteristic, lung CT scan quantitative data, respiratory function maximum respiratory support of not vaccinated patients admitted or not admitted in ICU. **Figure S5A.** Fully vaccinated and Not vaccinated Kaplan-Meier survival curves. **B.** Age strata KM survival curves survival.

Acknowledgements

Not applicable.

Author contributions

D.C., S.C., G.M. and A.D.M. designed the study; L.S., S.D.B., T.P., R.M., M.V., S.B., R.D. and C.Z. retrieved the data; A.T. and L.S. performed the analysis; D.C., G.M. and A.D.M. wrote the first draft of the manuscript; T.P., S.C. and L.C. revised the first draft of the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The data set used for this study is available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the institutional review board of the ASST Santi Paolo e Carlo Hospital (protocol number 2020/ST/049 and 2020/ST/049bis, 11 March 2020). The consent to participate was taken according to Italian regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 19 November 2022 Accepted: 27 January 2023

Published: 3 April 2023

References

1. Worldometer. COVID-19 Live—coronavirus statistics. <https://www.worldometers.info/coronavirus/>.
2. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* (London, England). 2020;395:1973–87.
3. Couture A, Iuliano AD, Chang HH, Patel NN, Gilmer M, Steele M, Havers FP, Whitaker M, Reed C. Estimating COVID-19 hospitalizations in the united states with surveillance data using a bayesian hierarchical model: modeling study. *JMIR Public Health Surveill*. 2022;8: e34296.
4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RWJ, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med*. 2020;383:2603–15.
5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N, Creech CB, McGottigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384:403–16.

6. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* (London, England). 2021;397:99–111.
7. EMA COVID-19 authorised vaccines—European Medicine Agency. <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#:~:text=EMA monitors the safety of,Safety of COVID-19 vaccines.>
8. CDC COVID-19 Vaccination—Center for Disease Control and Prevention. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>.
9. COVID-19 Opendata Vaccini. <https://github.com/italia/covid19-opendata-vaccini>.
10. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, Ghahmande S, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. *JAMA*. 2021;326:2043–54.
11. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, Ghahmande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CT, Busse L, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States. *medRxiv Prepr Serv Health Sci*. 2021.
12. Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O'Brien KL, Smith PG, Wilder-Smith A, Zeger S, Deloria Knoll M, Patel MK. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. *Lancet* (London, England). 2022;399:924–44.
13. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, DeSilva MB, Natarajan K, Bozio CH, Lewis N, Dascomb K, Dixon BE, Birch RJ, Irving SA, Rao S, Kharbanda E, Han J, Reynolds S, Goddard K, Grisel N, Fadel WF, Levy ME, Ferdinands J, Fireman B, Arndorfer J, Valvi NR, Rowley EA, Patel P, Zerbo O, Griggs EP, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. *N Engl J Med*. 2021;385:1355–71.
14. Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, Silk BJ, Gundlapalli AV, Harris AM, Boehmer TK, Kadri SS. Risk factors for severe COVID-19 outcomes among persons aged ≥ 18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020–October 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71:19–25.
15. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Neshet L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-Well Y. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021;27:1652–7.
16. Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, Seppälä E, Golestani K, Kvåle R, Watle SV, Buanes EA. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. *Clin Microbiol Infect*. 2022;28:871–8.
17. d'Arminio Monforte A, Tavelli A, De Benedittis S, Bai F, Tincati C, Gazzola L, Viganò O, Allegrini M, Mondatore D, Tesoro D, Barbanotti D, Mulè G, Castoldi R, De Bona A, Bini T, Chiumello D, Centanni S, Passarella S, Orfeo N, Marchetti G, Cozzi-Lepri A, Grioup FTS. Real world estimate of vaccination protection in individuals hospitalized for COVID-19. *Vaccines*. 2022. <https://doi.org/10.3390/vaccines10040550>.
18. Lorenzoni G, Rosi P, De Rosa S, Ranieri VM, Navalesi P, Gregori D. COVID-19 vaccination status among adults admitted to intensive care units in Veneto, Italy. *JAMA Netw Open*. 2022;5:e2213553.
19. Hilty MP, Keiser S, Wendel Garcia PD, Moser A, Schuepbach RA. mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland. *Intensive Care Med*. 2022;48:362.
20. Mhawish H, Mady A, Alaklobi F, Aletreby W, Asad T, Alodat M, Alharthy A, Abdulrahman B, Almahwi S, Memish ZA. Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: a prospective observational study. *Ann Med Surg*. 2021;71:102951.
21. Estella Á, Cantón ML, Muñoz L, Higuera IR, Recuerda Núñez M, Tejero Aranguren J, Zaya B, Gómez C, Amaya R, Hurtado Martínez Á, Del Valle Otero Bernal M, De la Fuente C, Alados JC, Garnacho-Montero J, Samiuc OBOTGODOTASOICACU. Vaccinated patients admitted in ICU with severe pneumonia due to SARS-CoV-2: a multicenter pilot study. *J Pers Med*. 2021;11.
22. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. *J Am Coll Radiol*. 2020;17:701–9.
23. Di Meglio L, Carriero S, Biondetti P, Wood BJ, Carrafiello G. Chest imaging in patients with acute respiratory failure because of coronavirus disease 2019. *Curr Opin Crit Care*. 2022;28:17–24.
24. Ishfaq A, Yousaf Farooq SM, Goraya A, Yousaf M, Gilani SA, Kiran A, Ayoub M, Javed A, Bacha R. Role of high resolution computed tomography chest in the diagnosis and evaluation of COVID-19 patients—a systematic review and meta-analysis. *Eur J Radiol Open*. 2021;8:100350.
25. Brandi N, Ciccarese F, Rimondi MR, Balacchi C, Modolon C, Sportoletti C, Renzulli M, Coppola F, Golfieri R. An imaging overview of COVID-19 ARDS in ICU patients and its complications: a pictorial review. *Diagnostics*. 2022. <https://doi.org/10.3390/diagnostics12040846>.
26. Brandi N, Ciccarese F, Balacchi C, Rimondi MR, Modolon C, Sportoletti C, Capozzi C, Renzulli M, Paccapelo A, Castelli A, Golfieri R. Co-infections and superinfections in COVID-19 critically ill patients are associated with CT imaging abnormalities and the worst outcomes. *Diagnostics*. 2022;12:1–16.
27. Chiumello D, Papa GFS, Artigas A, Bouhemed B, Grgic A, Heunks L, Markstaller K, Pellegrino GM, Pisani L, Rigau D, Schultz MJ, Sotgiu G, Spieth P, Zompatori M, Navalesi P. ERS statement on chest imaging in acute respiratory failure. *Eur Respir J*. 2019;54:1900435.
28. Gattinoni L, Caironi P, Pelosi P, Goodman LR. What has computed tomography taught us about the acute respiratory distress syndrome? *Am J Respir Crit Care Med*. 2001;164:1701–11.
29. Bitker L, Talmor D, Richard J-C. Imaging the acute respiratory distress syndrome: past, present and future. *Intensive Care Med*. 2022;48:995–1008.
30. Chiumello D, Busana M, Coppola S, Romitti F, Formenti P, Bonifazi M, Pozzi T, Palumbo MM, Cressoni M, Herrmann P, Meissner K, Quintel M, Camporota L, Marini JJ, Gattinoni L. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. *Intensive Care Med*. 2020;46:2187–96.
31. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* (London, England). 2021;397:881–91.
32. Herrmann P, Busana M, Cressoni M, Lotz J, Moerer O, Saager L, Meissner K, Quintel M, Gattinoni L. Using artificial intelligence for automatic segmentation of CT lung images in acute respiratory distress syndrome. *Front Physiol*. 2021;12:676118.
33. Herrmann P, Nguyen X, Luecke T, Quintel M. MALUNA 1.03 a software tool for the analysis of computed tomographic slice images of the lung. *Jamal R, Jaschinski H. Published Online; 2002. p. 389–395.*
34. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, Møller CH, Ethelberg S, Legarth R, Button MSF, Gubbels S, Voldstedlund M, Molbak K, Skov RL, Fomsgaard A, Krause TG. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. 2021;21:1507–17.
35. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan B-A, Brooks MM,

- Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. *N Engl J Med*. 2021;385:790–802.
36. Ramos-Rincon J-M, Cobos-Palacios L, López-Sampalo A, Ricci M, Rubio-Rivas M, Nuñez-Rodríguez M-V, Miranda-Godoy R, García-Leoni M-E, Fernández-Madera-Martínez R, García-García G-M, Beato-Perez J-L, Monge-Monge D, Asín-Samper U, Bustamante-Vega M, Rábago-Lorite I, Freire-Castro S-J, Miramontes-González J-P, Magallanes-Gamboa J-O, Alcalá-Pedrajas J-N, García-Gómez M, Cano-Llorente V, Carrasco-Sánchez F-J, Martínez-Carrilero J, Antón-Santos J-M, Gómez-Huelgas R. Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain). *BMC Geriatr*. 2022;22:546.
 37. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8:475–81.
 38. Bell TD. COVID-19 in the critically ill patient. *Infect Dis Clin N Am*. 2022;36:365–77.
 39. Balacchi C, Brandi N, Ciccarese F, Coppola F, Lucidi V, Bartalena L, Parmeggiani A, Paccapelo A, Golfieri R. Comparing the first and the second waves of COVID-19 in Italy: differences in epidemiological features and CT findings using a semi-quantitative score. *Emerg Radiol*. 2021;28:1055–61.
 40. de Jaegere TMH, Krdzalic J, Fasen BACM, Kwee RM. Radiological Society of North America Chest CT Classification System for reporting COVID-19 pneumonia: interobserver variability and correlation with reverse-transcription polymerase chain reaction. *Radiol Cardiothorac Imaging*. 2020;2:e200213.
 41. Fatima S, Zafar A, Afzal H, Ejaz T, Shamim S, Saleemi S, Subhan BA. COVID-19 infection among vaccinated and unvaccinated: Does it make any difference? *PLoS ONE*. 2022;17: e0270485.
 42. Gattinoni L, Cressoni M. Quantitative CT in ARDS: towards a clinical tool? *Intensive Care Med*. 2010;36:1803–4.
 43. Pellegrini M, Larina A, Mourtos E, Frithiof R, Lipcsey M, Hultström M, Segelsjö M, Hansen T, Perchiazzi G. A quantitative analysis of extension and distribution of lung injury in COVID-19: a prospective study based on chest computed tomography. *Crit Care*. 2021;25:276.
 44. Ball L, Robba C, Herrmann J, Gerard SE, Xin Y, Mandelli M, Battaglini D, Brunetti I, Minetti G, Seitun S, Bovio G, Vena A, Giacobbe DR, Bassetti M, Rocco PRM, Cereda M, Rizi RR, Castellan L, Patroniti N, Pelosi P. Lung distribution of gas and blood volume in critically ill COVID-19 patients: a quantitative dual-energy computed tomography study. *Crit Care*. 2021;25:214.
 45. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, Chen N-W. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: a multicenter cohort study. *Lancet Reg Health Am*. 2021;4: 100065.
 46. Motos A, López-Gavín A, Riera J, Ceccato A, Fernández-Barat L, Bermejo-Martin JF, Ferrer R, de Gonzalo-Calvo D, Menéndez R, Pérez-Arnal R, García-Gasulla D, Rodríguez A, Peñuelas O, Lorente JA, Almansa R, Gabarús A, Marin-Corral J, Ricart P, Roche-Campo F, Sancho Chinesta S, Socias L, Barbé F, Torres A. Higher frequency of comorbidities in fully vaccinated patients admitted to the ICU due to severe COVID-19: a prospective, multicentre, observational study. *Eur Respir J*. 2022. <https://doi.org/10.1183/13993003.02275-2021>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► [springeropen.com](https://www.springeropen.com)
